1. Article › Research › Peer-reviewed
2. Published

   Biosimilars: Evidential standards for health technology assessment.

   Hughes, D. & Hughes, D. A., 1 Mar 2010, In: Clinical Pharmacology and Therapeutics. 87, 3, p. 257-261

   Research output: Contribution to journal › Article › peer-review

3. Published

   Drugs for exceptionally rare diseases: do they deserve special status for funding?

   Hughes, D., Tunnage, B. & Yeo, S. T., 1 Nov 2005, In: QJM - An International Journal of Medicine. 98, 11, p. 829-836

   Research output: Contribution to journal › Article › peer-review

4. Published

   HTAs and rare diseases: How to assess their cost-effectiveness

   Hughes, D., Phillips, C. J. & Hughes, D. A., 1 Nov 2011, In: Pharmaceuticals Policy and Law. 13, 3-4, p. 161-165

   Research output: Contribution to journal › Article › peer-review

5. Published

   Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain

   Hughes, D., Linley, W. G. & Hughes, D. A., 1 Aug 2013, In: Health Economics. 22, 8, p. 948-964

   Research output: Contribution to journal › Article › peer-review